Olanzapine: Difference between revisions

Revision as of 23:16, 17 June 2004 editJfdwolff (talk \| contribs)Administrators81,547 edits site descriptors← Previous edit		Revision as of 23:16, 17 June 2004 edit undoJfdwolff (talk \| contribs)Administrators81,547 editsm tyopNext edit →
Line 7:		Line 7:

	==Side effects==		==Side effects==
	Common side effects include ] symptoms: ] rigidity, stiffness and twitches, restlessness and ]. ], ] and ] are longer-term concerns that may affect the development of ] later on in life.		Common side effects include ] symptoms: ] rigidity, stiffness and twitches, restlessness and ]. ], ] and ] are longer-term concerns that may affect the development of ] later on in life.

	Olanzapine is reported to cause ] and ], although at a much reduced rate when compared to the classical antipsychotics.		Olanzapine is reported to cause ] and ], although at a much reduced rate when compared to the classical antipsychotics.

Revision as of 23:16, 17 June 2004

Olanzapine (Zyprexa® or in a combination with fluoxetine as Symbyax®) is one of the most commonly used atypical antipsychotics. Olanzapine has been FDA approved for the treatment of schizophrenia, acute mania in bipolar disorder, and as maintenance treatment in bipolar disorder. Olanzapine is manufactured and marketed by the pharmaceutical company Eli Lilly and Company.

In December 2003 the FDA approved Symbyax to treat the depressive phase of bipolar disorder.

Since the ascendancy of atypical antipsychotics, olanzapine has become a frequently-used first line agent for acute psychosis and schizophrenia.

Common side effects include extrapyramidal symptoms: muscle rigidity, stiffness and twitches, restlessness and sedation. Weight gain, obesity and diabetes mellitus are longer-term concerns that may affect the development of cardiovascular disease later on in life.

Olanzapine is reported to cause tardive dyskinesia and neurological malignant syndrome, although at a much reduced rate when compared to the classical antipsychotics.